BR112022021258A2 - Composições e métodos para prevenir, controlar e diagnosticar infecções micobacterianas - Google Patents

Composições e métodos para prevenir, controlar e diagnosticar infecções micobacterianas

Info

Publication number
BR112022021258A2
BR112022021258A2 BR112022021258A BR112022021258A BR112022021258A2 BR 112022021258 A2 BR112022021258 A2 BR 112022021258A2 BR 112022021258 A BR112022021258 A BR 112022021258A BR 112022021258 A BR112022021258 A BR 112022021258A BR 112022021258 A2 BR112022021258 A2 BR 112022021258A2
Authority
BR
Brazil
Prior art keywords
prevent
control
compositions
methods
mycobacterial infections
Prior art date
Application number
BR112022021258A
Other languages
English (en)
Inventor
Facciuolo Antonio
Griebel Philip
Gerdts Volker
Potter Andrew
Rawlyk Neil
Chen Jeffrey
Pastural Elodie
Bains Manjeet
Trimble Michael
Lee Amy
Hancock Robert
Original Assignee
Univ Saskatchewan
Univ British Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Saskatchewan, Univ British Columbia filed Critical Univ Saskatchewan
Publication of BR112022021258A2 publication Critical patent/BR112022021258A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/5695—Mycobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A40/00—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production
    • Y02A40/70—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production in livestock or poultry

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

COMPOSIÇÕES E MÉTODOS PARA PREVENIR, CONTROLAR E DIAGNOSTICAR INFECÇÕES MICOBACTERIANAS. São descritos antígenos micobacterianos, como antígenos MAP e M. bovis. Os antígenos podem ser usados em composições de subunidades para induzir respostas imunes para prevenir e/ou controlar infecções micobacterianas, bem como em diagnósticos para detectar mamíferos infectados com micobactérias.
BR112022021258A 2020-04-20 2021-04-19 Composições e métodos para prevenir, controlar e diagnosticar infecções micobacterianas BR112022021258A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063012668P 2020-04-20 2020-04-20
PCT/CA2021/050527 WO2021212215A1 (en) 2020-04-20 2021-04-19 Compositions and methods for preventing, controlling and diagnosing mycobacterial infections

Publications (1)

Publication Number Publication Date
BR112022021258A2 true BR112022021258A2 (pt) 2023-01-17

Family

ID=78270853

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022021258A BR112022021258A2 (pt) 2020-04-20 2021-04-19 Composições e métodos para prevenir, controlar e diagnosticar infecções micobacterianas

Country Status (8)

Country Link
US (1) US20230218734A1 (pt)
EP (1) EP4138894A4 (pt)
AU (1) AU2021258911A1 (pt)
BR (1) BR112022021258A2 (pt)
CA (1) CA3176303A1 (pt)
CL (1) CL2022002893A1 (pt)
MX (1) MX2022013152A (pt)
WO (1) WO2021212215A1 (pt)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0972045A1 (en) * 1997-04-02 2000-01-19 Statens Seruminstitut NUCLEIC ACID FRAGMENTS AND POLYPEPTIDE FRAGMENTS DERIVED FROM $i(M. TUBERCULOSIS)
EP1029053A1 (en) * 1997-11-10 2000-08-23 Statens Seruminstitut Nucleic acid fragments and polypeptide fragments derived from mycobacterium tuberculosis
US7074559B2 (en) * 2002-03-06 2006-07-11 Refents of the University of Minnesota Mycobacterial diagnostics
WO2007108829A2 (en) * 2005-10-26 2007-09-27 Gene Therapy Systems, Inc. Tuberculosis nucleic acids, polypeptides and immunogenic compositions
US7846420B2 (en) * 2007-04-23 2010-12-07 Greenstein Robert J Mycobacterium avium subspecies paratuberculosis vaccines and methods of using the same
EP2271760A2 (en) * 2008-04-29 2011-01-12 Monsanto Technology LLC Genes and uses for plant enhancement
EP2437061A1 (en) * 2010-09-30 2012-04-04 Ikonomopoulos, John Mycobacterial protein detection
WO2019144139A1 (en) * 2018-01-22 2019-07-25 Oregon State University Immunogenic compositions comprising mycobacterium bovis surface proteins and uses thereof
CN110606875A (zh) * 2019-09-20 2019-12-24 中国农业科学院兰州兽医研究所 一种用于制备口蹄疫疫苗的分子内佐剂及其应用和口蹄疫疫苗

Also Published As

Publication number Publication date
WO2021212215A1 (en) 2021-10-28
US20230218734A1 (en) 2023-07-13
CA3176303A1 (en) 2021-10-28
EP4138894A1 (en) 2023-03-01
AU2021258911A1 (en) 2022-11-24
CL2022002893A1 (es) 2023-06-30
EP4138894A4 (en) 2024-06-26
MX2022013152A (es) 2023-02-09

Similar Documents

Publication Publication Date Title
HRP20181711A2 (hr) Sustavi i metode za pružanje višefaktorske verifikacije osobnog identiteta na temelju lanca blokova
CL2019001480A1 (es) Receptores inmunes sintéticos y métodos de uso de los mismos.
EA201990566A1 (ru) Композиции, содержащие бактериальные штаммы
WO2014063704A8 (en) M. tuberculosis vaccines
MY173004A (en) Mycobacterial antigen vaccine
MX2016009809A (es) Polipéptidos efectores de la subunidad a de la toxina shiga desinmunizada para aplicaciones en mamíferos.
BR112016015936A2 (pt) Combinação imunogênica, molécula de ácido nucleico, vetor, célula hospedeira, método de produção recombinante dos antígenos e composição
BR112016015503A8 (pt) "método, sistema e veículo para sumário pós-direção com tutorial
BR112016023778A2 (pt) proteína de fusão ou coquetel antígeno, uso de uma proteína de fusão ou coquetel antígeno, vacina, e método para a imunização de um animal, incluindo um ser humano, contra a tuberculose causada por micobactérias virulentas
BR112015019283A2 (pt) composições e métodos de aprimoramento de respostas imunes à eiméria ou infecção por eiméria limitadora
BR112016028032A2 (pt) Sais de amônio quaternário acoplados
BR112017016897A2 (pt) cepas fúngicas e métodos de uso
BR112016019837A2 (pt) plasmídeos imunoestimuladores
BR112015019865A2 (pt) composições de copolímero de alfa-olefina de alta viscosidade e métodos de preparação e uso das mesmas
AR081418A1 (es) Medio legible por computadora, metodo y sistema para proporcionar la admisnitracion de un sistema basado en busquedas
MX2018014270A (es) Composiciones y metodos para tratar la tuberculosis secundaria e infecciones po micobacteria no tuberculosa.
BR112019000166A2 (pt) anticorpos com baixa imunogenicidade e usos dos mesmos
WO2011135369A8 (en) Diagnostic reagents
AR101715A1 (es) Composiciones útiles para diagnosticar infección latente por mycobacterium tuberculosis
PT115304A (pt) Procedimento de login com um clique
Siddiqui et al. Understanding the biology of 16 kDa antigen of Mycobacterium tuberculosis: scope in diagnosis, vaccine design and therapy
BR112022021258A2 (pt) Composições e métodos para prevenir, controlar e diagnosticar infecções micobacterianas
BR112015012762A2 (pt) antígenos de pseudomonas e combinações de antígenos
BR112015028583A8 (pt) membranas de osmose avançada compreendendo polianilina e método para sua formação
WO2015061610A3 (en) Human t cell line assay for evaluating the immunologic identity of glatiramer acetate preparations